Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | CLPP | Q16740 | 1/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.31 |
| ▸ | NMT1 | P30419 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31661569 | 0.83 | CYP11B2 (0.37) | CYP11B2 | |
| SCHEMBL2648424 | 0.64 | BPTF (0.44) | — | |
| SCHEMBL31661776 | 0.57 | KRAS (0.36) | — | |
| SCHEMBL18255822 | 0.57 | CYP11B2 (0.59) | CYP11B2CSNK1A1CSNK1DGSK3BCSNK1G2 | |
| SCHEMBL12643489 | 0.56 | PLAUR (0.34) | — | |
| SCHEMBL18255779 | 0.55 | CYP11B2 (0.47) | CYP11B2CSNK1A1CSNK1DGSK3BCSNK1G2 | |
| SCHEMBL19243902 | 0.54 | CYP11B2 (0.44) | CYP11B2GSK3B | |
| SCHEMBL12643259 | 0.54 | BPTF (0.39) | — | |
| SCHEMBL12643317 | 0.54 | ADORA1 (0.38) | — | |
| SCHEMBL27785043 | 0.54 | CYP11B2 (0.66) | CYP11B2CSNK1A1CSNK1DGSK3BCSNK1G2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151705-A1 | NOVEL INHIBITORS OF DNA DAMAGE REPAIR PATHWAY | VRISE THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2025151705-A1 | NOVEL INHIBITORS OF DNA DAMAGE REPAIR PATHWAY | VRISE THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | disclosed |